Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions.

Chu DZ, Hussey MA, Alberts DS, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE.

Clin Colorectal Cancer. 2011 Dec;10(4):310-6. doi: 10.1016/j.clcc.2011.06.005. Epub 2011 Jul 22.

2.

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.

Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD.

Ann Oncol. 2011 Dec;22(12):2610-5. doi: 10.1093/annonc/mdr021. Epub 2011 Mar 17.

3.

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD.

J Clin Oncol. 2010 Aug 1;28(22):3605-10. doi: 10.1200/JCO.2009.25.7550. Epub 2010 Jul 6.

4.

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL.

J Clin Oncol. 2006 Oct 20;24(30):4922-7. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334.

PMID:
17050876
5.

Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.

Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2190-5. Epub 2006 Feb 6.

6.

Microsatellite instability as a predictor of survival in head and neck cancer -- is there a link with colon cancer?

Gleich LL, Wang J, Gluckman JL, Fenoglio-Preiser CM.

ORL J Otorhinolaryngol Relat Spec. 2003 Jul-Aug;65(4):193-8.

PMID:
14564091
7.

Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study.

Chu DZ, Chansky K, Alberts DS, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Goodman GE, Abbruzzese JL, Lippman SM.

Ann Surg Oncol. 2003 Oct;10(8):870-5.

8.

TP53 and gastric carcinoma: a review.

Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A.

Hum Mutat. 2003 Mar;21(3):258-70. Review.

PMID:
12619111
9.

Reliability in the classification of advanced colorectal adenomas.

Terry MB, Neugut AI, Bostick RM, Potter JD, Haile RW, Fenoglio-Preiser CM.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):660-3.

10.

Risk factors for advanced colorectal adenomas: a pooled analysis.

Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS, Fenoglio-Preiser CM, Potter JD.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9.

11.

Gastrointestinal neuroendocrine/neuroectodermal tumors.

Fenoglio-Preiser CM.

Am J Clin Pathol. 2001 Jun;115 Suppl:S79-93. Review.

PMID:
11993693
12.

A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene.

Noffsinger AE, Belli JM, Miller MA, Fenoglio-Preiser CM.

Histopathology. 2001 Nov;39(5):482-92.

PMID:
11737306
13.

The Vienna classification of gastrointestinal epithelial neoplasia.

Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H.

Gut. 2000 Aug;47(2):251-5.

14.

Microsatellite instability and K-ras mutations in patients with ulcerative colitis.

Lyda MH, Noffsinger A, Belli J, Fenoglio-Preiser CM.

Hum Pathol. 2000 Jun;31(6):665-71.

PMID:
10872658
15.

American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.

Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP.

Cancer. 2000 Apr 1;88(7):1739-57. Review.

PMID:
10738234
16.

Aberrant crypt foci: A review.

Fenoglio-Preiser CM, Noffsinger A.

Toxicol Pathol. 1999 Nov-Dec;27(6):632-42. Review. No abstract available.

PMID:
10588543
17.

Have we thrown the baby out with the bath water?

Fenoglio-Preiser CM.

Dig Dis. 1999;17(2):65-6. No abstract available.

PMID:
10545711
18.

Carboxyl ester lipase activity in milk prevents fat-derived intestinal injury in neonatal mice.

Howles PN, Stemmerman GN, Fenoglio-Preiser CM, Hui DY.

Am J Physiol. 1999 Sep;277(3):G653-61. doi: 10.1152/ajpgi.1999.277.3.G653.

19.

When is a hyperplastic polyp not a hyperplastic polyp?

Fenoglio-Preiser CM.

Am J Surg Pathol. 1999 Sep;23(9):1001-3. No abstract available.

PMID:
10478658
20.

Microsatellite instability is absent in liver and biliary mucosa of patients with primary sclerosing cholangitis.

Jin SY, Noffsinger AE, Bejarano P, Weber FL Jr, Hanto DW, Belli JM, Fenoglio-Preiser CM.

Dig Dis Sci. 1999 Mar;44(3):595-601.

PMID:
10080156
21.

p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.

Tolbert DM, Noffsinger AE, Miller MA, DeVoe GW, Stemmermann GN, Macdonald JS, Fenoglio-Preiser CM.

Mod Pathol. 1999 Jan;12(1):54-60.

PMID:
9950163
22.

A germline hMSH2 alteration is unrelated to colonic microsatellite instability in patients with ulcerative colitis.

Noffsinger AE, Belli JM, Fogt F, Fischer J, Goldman H, Fenoglio-Preiser CM.

Hum Pathol. 1999 Jan;30(1):8-12.

PMID:
9923920
23.

Increased cell proliferation characterizes Crohn's disease.

Noffsinger A, Unger B, Fenoglio-Preiser CM.

Mod Pathol. 1998 Dec;11(12):1198-203.

PMID:
9872652
24.

Multifocal neoplasia involving the colon and appendix in ulcerative colitis: pathological and molecular features.

Lyda MH, Noffsinger A, Belli J, Fischer J, Fenoglio-Preiser CM.

Gastroenterology. 1998 Dec;115(6):1566-73.

PMID:
9834286
25.

Adenoma-carcinoid tumors of the colon.

Lyda MH, Fenoglio-Preiser CM.

Arch Pathol Lab Med. 1998 Mar;122(3):262-5.

PMID:
9823866
26.

Aggressiveness of colon carcinoma in blacks and whites. National Cancer Institute Black/White Cancer Survival Study Group.

Chen VW, Fenoglio-Preiser CM, Wu XC, Coates RJ, Reynolds P, Wickerham DL, Andrews P, Hunter C, Stemmermann G, Jackson JS, Edwards BK.

Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):1087-93.

27.

Regenerative lesions in ulcerative colitis are characterized by microsatellite mutation.

Heinen CD, Noffsinger AE, Belli J, Straughen J, Fischer J, Groden J, Fenoglio-Preiser CM.

Genes Chromosomes Cancer. 1997 Jul;19(3):170-5.

PMID:
9218998
28.

Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinomas.

Sheyn I, Noffsinger AE, Heffelfinger S, Davis B, Miller MA, Fenoglio-Preiser CM.

Hum Pathol. 1997 Mar;28(3):270-6.

PMID:
9042789
29.

The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis.

Noffsinger AE, Miller MA, Cusi MV, Fenoglio-Preiser CM.

Cancer. 1996 Dec 1;78(11):2307-12.

PMID:
8940999
30.

Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer. A comparative study.

Heffelfinger SC, Lower EE, Miller MA, Fenoglio-Preiser CM.

Am J Clin Oncol. 1996 Dec;19(6):552-7.

PMID:
8931669
31.

Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach.

Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC.

Am J Pathol. 1996 Nov;149(5):1449-57.

32.

Re: E. Farber, Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res., 55: 3759-3762, 1995.

Stemmermann GN, Noffsinger A, Fenoglio-Preiser CM.

Cancer Res. 1996 Sep 15;56(18):4267; author reply 4272-4. No abstract available.

33.

Hematologic malignancies developing in Syrian golden hamsters during induction of pancreatic carcinoma.

Cualing HD, Povoski SP, Yassin RS, Fenoglio-Preiser CM, Bell RH Jr.

Carcinogenesis. 1996 Sep;17(9):1983-8.

PMID:
8824524
34.

Detection of human papillomavirus in esophageal squamous cell carcinoma.

Suzuk L, Noffsinger AE, Hui YZ, Fenoglio-Preiser CM.

Cancer. 1996 Aug 15;78(4):704-10.

PMID:
8756360
35.

Pathologic and phenotypic features of gastric cancer.

Fenoglio-Preiser CM, Noffsinger AE, Belli J, Stemmermann GN.

Semin Oncol. 1996 Jun;23(3):292-306.

PMID:
8658213
36.

Determinants of black/white differences in colon cancer survival.

Mayberry RM, Coates RJ, Hill HA, Click LA, Chen VW, Austin DF, Redmond CK, Fenoglio-Preiser CM, Hunter CP, Haynes MA, et al.

J Natl Cancer Inst. 1995 Nov 15;87(22):1686-93.

PMID:
7473817
37.

Esophageal heterotopic pancreas presenting as an inflammatory mass.

Noffsinger AE, Hyams DM, Fenoglio-Preiser CM.

Dig Dis Sci. 1995 Nov;40(11):2373-9.

PMID:
7587817
38.

Malignant mixed müllerian tumor of the extraovarian secondary müllerian system. Report of two cases and review of the English literature.

Mira JL, Fenoglio-Preiser CM, Husseinzadeh N.

Arch Pathol Lab Med. 1995 Nov;119(11):1044-9. Review.

PMID:
7487405
39.

Differential sensitivities of E6 type-specific and L1 consensus primers in the detection of human papillomavirus in anal carcinoma.

Noffsinger AE, Suzuk L, Hui YZ, Gal AA, Fenoglio-Preiser CM.

Mod Pathol. 1995 Jun;8(5):509-14.

PMID:
7675769
40.

The relationship of human papillomavirus to proliferation and ploidy in carcinoma of the anus.

Noffsinger AE, Hui YZ, Suzuk L, Yochman LK, Miller MA, Hurtubise P, Gal AA, Fenoglio-Preiser CM.

Cancer. 1995 Feb 15;75(4):958-67.

PMID:
7842416
41.

Anatomic site distribution of colon cancer by race and other colon cancer risk factors.

Coates RJ, Greenberg RS, Liu MT, Correa P, Harlan LC, Reynolds P, Fenoglio-Preiser CM, Haynes MA, Hankey BF, Hunter CP, et al.

Dis Colon Rectum. 1995 Jan;38(1):42-50.

PMID:
7813344
42.

The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors.

Stemmermann G, Heffelfinger SC, Noffsinger A, Hui YZ, Miller MA, Fenoglio-Preiser CM.

Hum Pathol. 1994 Oct;25(10):968-81. Review.

PMID:
7927320
43.

Pathology and laboratory medicine.

Fenoglio-Preiser CM, Pesce AJ.

JAMA. 1993 Jul 14;270(2):245-6. No abstract available.

PMID:
8315749
44.

Effect of streptozotocin diabetes on development of nitrosamine-induced pancreatic carcinoma when diabetes induction occurs after nitrosamine exposure.

Povoski SP, Fenoglio-Preiser CM, Sayers HJ, McCullough PJ, Zhou W, Bell RH Jr.

Carcinogenesis. 1993 May;14(5):961-7.

PMID:
8504490
45.

The future of prognostic factors in outcome prediction for patients with cancer.

Fielding LP, Fenoglio-Preiser CM, Freedman LS.

Cancer. 1992 Nov 1;70(9):2367-77. Review.

PMID:
1394064
46.

The relationship of human papillomaviruses to anorectal neoplasia.

Noffsinger A, Witte D, Fenoglio-Preiser CM.

Cancer. 1992 Sep 1;70(5 Suppl):1276-87. Review.

PMID:
1324782
48.

Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer.

Fenoglio-Preiser CM.

Cancer. 1992 Mar 15;69(6 Suppl):1607-32. Review.

PMID:
1540902
49.

Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia.

Longacre TA, Fenoglio-Preiser CM.

Am J Surg Pathol. 1990 Jun;14(6):524-37. Review.

PMID:
2186644
50.

Colorectal adenomas containing invasive carcinoma. Pathologic assessment of lymph node metastatic potential.

Coverlizza S, Risio M, Ferrari A, Fenoglio-Preiser CM, Rossini FP.

Cancer. 1989 Nov 1;64(9):1937-47. Review.

PMID:
2477139

Supplemental Content

Loading ...
Support Center